315 related articles for article (PubMed ID: 18089874)
21. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials.
Francart J; Vaes E; Henrard S; Legrand C; Baas P; Gaafar R; van Meerbeeck JP; Sylvester R; Robert A
Eur J Cancer; 2009 Sep; 45(13):2304-11. PubMed ID: 19502050
[TBL] [Abstract][Full Text] [Related]
22. Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.
Matsuzaki Y; Tomita M; Shimizu T; Hara M; Ayabe T; Onitsuka T
Ann Thorac Cardiovasc Surg; 2008 Jun; 14(3):161-5. PubMed ID: 18577894
[TBL] [Abstract][Full Text] [Related]
23. [First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma].
Burgin M; Gairard-Dory A-; Mennecier B; Molard A; Beretz L; Quoix A-
Rev Pneumol Clin; 2009 Apr; 65(2):75-83. PubMed ID: 19375046
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors for 100 patients with malignant pleural mesothelioma.
Gonlugur U; Gonlugur TE
Arch Environ Occup Health; 2010; 65(2):65-9. PubMed ID: 20439224
[TBL] [Abstract][Full Text] [Related]
25. Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
Porta C; Zimatore M; Bonomi L; Imarisio I; Paglino C; Sartore-Bianchi A; Mutti L
Lung Cancer; 2005 Jun; 48(3):429-34. PubMed ID: 15893013
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
Lucchi M; Chella A; Melfi F; Dini P; Ambrogi M; Fino L; Fontanini G; Mussi A
Eur J Cardiothorac Surg; 2007 Mar; 31(3):529-33; discussion 533-4. PubMed ID: 17188885
[TBL] [Abstract][Full Text] [Related]
27. Life after first-line chemotherapy in malignant pleural mesothelioma: a North-East England experience.
Steer J; Bough G; Razak AR; Meachery GJ; Hughes A
Clin Oncol (R Coll Radiol); 2010 Apr; 22(3):231-5. PubMed ID: 20346340
[TBL] [Abstract][Full Text] [Related]
28. Raltitrexed and pemetrexed studies in mesothelioma have not shown improved quality of life nor prolonged survival compared with effective pleurodesis with thoracoscopic talc poudrage.
Aelony Y
J Clin Oncol; 2006 Oct; 24(28):4667; author reply 4667-8. PubMed ID: 17008709
[No Abstract] [Full Text] [Related]
29. Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma.
Trafalis DT; Alifieris C; Krikelis D; Tzogkas N; Stathopoulos GP; Athanassiou AE; Sitaras NM
Int J Clin Pharmacol Ther; 2012 Jul; 50(7):490-9. PubMed ID: 22578202
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
Tomek S; Manegold C
Lung Cancer; 2004 Aug; 45 Suppl 1():S103-19. PubMed ID: 15261443
[TBL] [Abstract][Full Text] [Related]
31. Current concepts in chemotherapy for malignant pleural mesothelioma.
Sørensen JB
Clin Respir J; 2008 Apr; 2(2):74-9. PubMed ID: 20298310
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics.
Metintas M; Metintas S; Ucgun I; Gibbs AR; Harmanci E; Alatas F; Erginel S; Tel N; Pasaoglu O
Respir Med; 2001 Oct; 95(10):829-35. PubMed ID: 11601750
[TBL] [Abstract][Full Text] [Related]
33. Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy.
Meyer F; Fortin A; Gélinas M; Nabid A; Brochet F; Têtu B; Bairati I
J Clin Oncol; 2009 Jun; 27(18):2970-6. PubMed ID: 19451440
[TBL] [Abstract][Full Text] [Related]
34. Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma.
Jenkins P; Milliner R; Salmon C
Eur J Cancer; 2011 Sep; 47(14):2143-9. PubMed ID: 21658936
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of vinflunine in malignant pleural mesothelioma.
Talbot DC; Margery J; Dabouis G; Dark G; Taylor H; Boussemart H; Cadic V; Pinel MC; Rivière A; Ollivier L; Ruffié P
J Clin Oncol; 2007 Oct; 25(30):4751-6. PubMed ID: 17947722
[TBL] [Abstract][Full Text] [Related]
36. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
Neragi-Miandoab S; Richards WG; Sugarbaker DJ
Int J Surg; 2008 Aug; 6(4):293-7. PubMed ID: 18585112
[TBL] [Abstract][Full Text] [Related]
37. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
Tilleman TR; Richards WG; Zellos L; Johnson BE; Jaklitsch MT; Mueller J; Yeap BY; Mujoomdar AA; Ducko CT; Bueno R; Sugarbaker DJ
J Thorac Cardiovasc Surg; 2009 Aug; 138(2):405-11. PubMed ID: 19619785
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors in mesothelioma.
Steele JP; Klabatsa A; Fennell DA; Palläska A; Sheaff MT; Evans MT; Shamash J; Rudd RM
Lung Cancer; 2005 Jul; 49 Suppl 1():S49-52. PubMed ID: 15894403
[TBL] [Abstract][Full Text] [Related]
39. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
Yan TD; Boyer M; Tin MM; Wong D; Kennedy C; McLean J; Bannon PG; McCaughan BC
J Thorac Cardiovasc Surg; 2009 Sep; 138(3):619-24. PubMed ID: 19698846
[TBL] [Abstract][Full Text] [Related]
40. The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.
Hanauske AR
Lung Cancer; 2004 Aug; 45 Suppl 1():S121-4. PubMed ID: 15261444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
